期刊文献+

带有荧光素酶报告基因的可调控重组腺病毒载体的构建及表达 被引量:1

Construction of RU486 regulatable adenoviral vector containing luciferase gene and its expression in vitro
下载PDF
导出
摘要 目的:构建带有萤火虫荧光素酶报告基因的可调控腺病毒载体,并在SW620结肠癌细胞株中观察其调控表达.方法:将萤火虫荧光素酶luc基因和启动子,以及RU486调控系统构建成单一的穿梭载体PDC-RULUC,将其与Admax腺病毒包装系统的辅助质粒共转染293细胞后,构建出可调控的重组腺病毒载体.扩增后用最终稀释法测定了其滴度,并在SW620细胞中检测了其基因调控效果.结果:成功地构建了携带有RU486调控系统的可调控腺病毒载体Ad-RULUC,病毒滴度达到5.2×1013pfu/L.当给予诱导剂RU486后,腺病毒载体可以诱导表达荧光素酶,并在一定范围内两者呈正比,而没有RU486时,几乎没有报告基因的表达.结论:腺病毒Ad-RULUC能调控外源基因的表达,为基因调控研究和基因治疗提供了良好的工具. AIM: To construct RU486 regulatable replicationdefective recombinant adenovirus containing luciferase gene, and to detect its expression in SW620 cells. METHODS: The single shuttle vector named PDC-RULUC was constructed with molecular biological methods, which contained firefly luciferase reporter gene, promoter and RU486-inducible system. Recombinant adenovirus was produced after cotransfection of the shutter vector PDCRULUC and adenovirus DNA helper plasmid pBHGlox△E1,3Cre into 293 cells. After the amplification, the recombinant adenoviral titer was determined by end point dilution assay. Expression in SW620 cells was tested by Luciferase Reporter Assay. RESULTS: The regulatable recombinant adenovirus vector containing luciferase gene was identified by PCR. The virus titer of Ad-RULUC was 5.2 × 10^13 pfu/L in the absence of RU486, no significant luciferase activation was observed, whereas in the presence of RU486,activation of the luciferase was positively correlated with the inducer under definite range. CONCLUSION: A RU486 regulatable recombinant adenoviral vector containing luciferase gene is successfully constructed, which provides a good basis for further research on gene regulation and gene therapy.
出处 《第四军医大学学报》 北大核心 2008年第15期1352-1355,共4页 Journal of the Fourth Military Medical University
基金 国家自然科学基金(30571830)
关键词 腺病毒载体 基因调控 末非司酮 荧光素酶 recombinant adenovirus gene regulation RU486 lueiferase
  • 相关文献

参考文献10

  • 1Alba R, Bosch A, Chillon M. Gutless adenovirus: last-generation adeno,:irus for gene therapy[ J]. Gene Ther, 2005,12 ( Suppl 1 ) : S18 -27.
  • 2Weber W, Fussenegger M. Pharmacologic transgene control systems for gene therapy[J]. J Gene Med, 2006,8(5) :535 -556.
  • 3Weber W, Fussenegger M. Novel gene switches[ J]. Handb Exp Pharmacol, 2007,178:73 - 105.
  • 4Vilaboa N, Voellmy R. Regulatable gene expression systems for gene therapy[JJ. Curr Gene Ther, 2006,6(4) :421 -438.
  • 5Goverdhana S, Puntel M, Xiong W, et al. Regulatable gene expression systems for gene therapy applications: progress and future challenges[J]. Mol Ther, 2005,12(2) :189 -211.
  • 6Wang L, Hemandez-Alcoceba R, Shankar V, et al. Prolonged and inducible transgene expression in the liver using gutless adeno':irus: a potential therapy for liver cancer [ J ]. Gastroenterology, 2004, 126( 1 ) :278 -289.
  • 7Ng P, Parks RJ, Cummings DT, et al. A high-efficiency Cre/loxPbased system for construction of adenoviral vectors [ J ]. Hum Gene Ther, 1999,10 ( 16 ) :2667 - 2672.
  • 8Maeda M, Namikawa K, Kobayashi I, et al. Targeted gene therapy toward astrocytoma using a Cre/loxP-based adenovirus system [ J ]. Brain Res, 2006,1081 ( 1 ) :34 -43.
  • 9朱晓伟.tadalafil[J].国外医学(药学分册),2003,30(2):125-125. 被引量:266
  • 10He TC, Zhou S, da Costa LT, et al. A simplified system for generating recombinant adenoviruses [ J ]. Proc Natl Acad Sci U S A, 1998,95 ( 5 ) :2509-2514.

共引文献265

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部